ArticleSkin health and diseasePublished
Guselkumab treatment of psoriasis results in sustained reduction of systemic inflammatory biomarkers to week 48 in three phase III randomized controlled trials
Regional connection
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
- Institution
- Johnson & Johnson
- County
- Montgomery County
Publication record
- Type
- Article
- Venue
- Skin health and disease
- Published
- Topic
- Clinical care
- PubMed ID
- 42540023
- PubMed Central ID
- PMC13425078
- Open access
- Yes, open
- Added to directory
- Source checked